Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The legal battle over mifepristone — the drug used in the majority of U.S. abortions — is heating up again. The 5th U.S. Circuit Court of Appeals heard fresh arguments over whether to tighten prescribing rules, while the Supreme Court has already blocked any changes pending further review. Meanwhile, the FDA says it's conducting its own safety review, and providers are quietly preparing to pivot to misoprostol-only regimens if mifepristone access is curtailed.
The fight over mifepristone access is far from over. The 5th U.S. Circuit Court of Appeals recently heard arguments in a case brought by Louisiana's attorney general seeking to reinstate in-person dispensing requirements for the abortion pill — a rule the FDA eliminated in 2023. The case is one of several winding through the courts, even as the Supreme Court has already blocked any changes to prescribing rules while litigation continues. The FDA, whose scientists have repeatedly affirmed mifepristone's safety and efficacy, says it is conducting its own review of the drug's prescribing rules — though the timeline remains unclear.
The political backdrop is complicated: anti-abortion groups want the Trump administration to roll back telehealth access and enforce an 1873 law banning mailing of the pills, but public opinion polls consistently show most Americans support legal abortion access. Telehealth providers say they're ready to shift to misoprostol-only regimens if mifepristone becomes harder to obtain, though that approach is somewhat less effective.
By the Numbers:
Why it matters: The outcome of this legal battle could reshape reproductive healthcare access nationwide — not just in states with abortion bans. Reinstating in-person dispensing requirements would disproportionately burden rural, low-income, and minority patients who rely on telehealth. It could also set a precedent for courts to override FDA drug regulations more broadly, unsettling the entire pharmaceutical regulatory framework.
